A
Ahmed Mady
Researcher at King Saud Medical City
Publications - 52
Citations - 1872
Ahmed Mady is an academic researcher from King Saud Medical City. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 35 publications receiving 1483 citations. Previous affiliations of Ahmed Mady include Tanta University.
Papers
More filters
Journal ArticleDOI
Corticosteroid Therapy for Critically Ill Patients With Middle East Respiratory Syndrome
Yaseen M. Arabi,Yasser Mandourah,Fahad Al-Hameed,Anees Sindi,Ghaleb A. Almekhlafi,Mohamed A. Hussein,Jesna Jose,Ruxandra Pinto,Awad Al-Omari,Ayman Kharaba,Abdullah Almotairi,Al Khatib K,Basem Alraddadi,Sarah Shalhoub,Ahmed Abdulmomen,Ismeal Qushmaq,Ahmed Mady,Othman Solaiman,Abdulsalam M. Al-Aithan,Rajaa Al-Raddadi,Ahmed Ragab,Hanan H. Balkhy,Al Harthy A,Ahmad M. Deeb,Al Mutairi H,Abdulaziz Al-Dawood,Laura Merson,Frederick G. Hayden,Frederick G. Hayden,Rob Fowler +29 more
TL;DR: Corticosteroid therapy in patients with MERS was not associated with a difference in mortality after adjustment for time‐varying confounders but was associated with delayed MERS coronavirus RNA clearance.
Journal ArticleDOI
Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study.
Yaseen M. Arabi,Sarah Shalhoub,Yasser Mandourah,Fahad Al-Hameed,Awad Al-Omari,Eman Al Qasim,Jesna Jose,Basem Alraddadi,Abdullah Almotairi,Kasim Al Khatib,Ahmed Abdulmomen,Ismael Qushmaq,Anees Sindi,Ahmed Mady,Ahmed Mady,Othman Solaiman,Rajaa Al-Raddadi,Khalid Maghrabi,Ahmed Ragab,Ghaleb A. Al Mekhlafi,Hanan H. Balkhy,Abdulrahman Al Harthy,Ayman Kharaba,Jawaher Gramish,Abdulsalam M. Al-Aithan,Abdulaziz Al-Dawood,Laura Merson,Frederick G. Hayden,Frederick G. Hayden,Robert A. Fowler +29 more
TL;DR: RBV/rIFN therapy was commonly used in critically ill MERS patients but was not associated with reduction in 90-day mortality or in faster MERS-CoV RNA clearance.
Journal ArticleDOI
Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study.
Yaseen M. Arabi,Awad Al-Omari,Yasser Mandourah,Fahad Al-Hameed,Anees Sindi,Basem Alraddadi,Sarah Shalhoub,Abdullah Almotairi,Kasim Al Khatib,Ahmed Abdulmomen,Ismael Qushmaq,Ahmed Mady,Othman Solaiman,Abdulsalam M. Al-Aithan,Rajaa Al-Raddadi,Ahmed Ragab,Ghaleb A. Al Mekhlafi,Abdulrahman Al Harthy,Ayman Kharaba,Mashael Al Ahmadi,Musharaf Sadat,Hanan Al Mutairi,Eman Al Qasim,Jesna Jose,Maliha Nasim,Abdulaziz Al-Dawood,Laura Merson,Robert A. Fowler,Frederick G. Hayden,Hanan H. Balkhy +29 more
TL;DR: Substantial overlap exists in the clinical presentation and comorbidities among patients with Middle East respiratory syndrome severe acute respiratory infection from other etiologies; therefore, a high index of suspicion combined with diagnostic testing is essential component of severe acute lungs infection investigation for at-risk patients.
Journal ArticleDOI
Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial.
Yaseen M. Arabi,Yaseen M. Arabi,Ayed Y. Asiri,Abdullah M. Assiri,Hani Jokhdar,Adel Alothman,Adel Alothman,Hanan H. Balkhy,Hanan H. Balkhy,Sameera Aljohani,Sameera Aljohani,Shmeylan Al Harbi,Shmeylan Al Harbi,Suleiman Kojan,Suleiman Kojan,Majed Al Jeraisy,Majed Al Jeraisy,Ahmad M. Deeb,Ahmad M. Deeb,Ziad A. Memish,Ziad A. Memish,Sameeh S. Ghazal,Sarah Al Faraj,Fahad Al-Hameed,Fahad Al-Hameed,Asim Alsaedi,Asim Alsaedi,Yasser Mandourah,Ghaleb A. Al Mekhlafi,Nisreen Murad Sherbeeni,Fatehi Elzein,Abdullah Almotairi,Ali Al Bshabshe,Ayman Kharaba,Jesna Jose,Abdulrahman Al Harthy,Mohammed Al Sulaiman,Ahmed Mady,Ahmed Mady,Robert A. Fowler,Robert A. Fowler,Frederick G. Hayden,Abdulaziz Al-Dawood,Abdulaziz Al-Dawood,Mohamed Abdelzaher,Wail Bajhmom,Mohamed A. Hussein,Mohamed A. Hussein +47 more
TL;DR: The aim of this article is to describe the statistical analysis plan for the MIRACLE trial, which is the first randomized controlled trial for MERS treatment, and the primary outcome is 90-day mortality.
Journal ArticleDOI
Macrolides in critically ill patients with Middle East Respiratory Syndrome.
Yaseen M. Arabi,Yaseen M. Arabi,Ahmad M. Deeb,Fahad Al-Hameed,Fahad Al-Hameed,Yasser Mandourah,Ghaleb A. Almekhlafi,Anees Sindi,Awad Al-Omari,Sarah Shalhoub,Ahmed Mady,Ahmed Mady,Basem Alraddadi,Abdullah Almotairi,Kasim Al Khatib,Ahmed Abdulmomen,Ismael Qushmaq,Othman Solaiman,Abdulsalam M. Al-Aithan,Abdulsalam M. Al-Aithan,Rajaa Al-Raddadi,Ahmad Ragab,Abdulrahman Al Harthy,Ayman Kharaba,Jesna Jose,Tarek Al Dabbagh,Tarek Al Dabbagh,Robert A. Fowler,Robert A. Fowler,Hanan H. Balkhy,Hanan H. Balkhy,Laura Merson,Frederick G. Hayden +32 more
TL;DR: It is indicated that macrolide therapy is not associated with a reduction in 90-day mortality or improvement in MERS-CoV RNA clearance.